Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Polarean has received 510(k) clearance from the FDA for the Company’s specialized MRI chest coil to now include its use with Philips 3.0T MRI scanners for the visualization of the Xenon-129 (129Xe) nuclei. This milestone further supports the recently announced collaboration with Philips.
BUSINESS | INTERVIEW
Our flu drug is not to be sniffed at, says Poolbeg Pharma chief Jeremy SkillingtonJeremy Skillington is tackling life-threatening influenza at stock market-bound spin-out Poolbeg Pharma
Jeremy Skillington wants to develop a “conveyor belt of therapies” after focusing on influenza
JASON CLARKE
Brian Carey
Sunday June 20 2021, 12.01am, The Sunday Times
Worth a sunday listen Justin waite from vox markets ( very knowledgeable and well researched guy )talks about his mistake of selling out of orph to early. 33 mins 10 sec in.
https://twitter.com/SharePickers/status/1363100303864774663?s=19
Re Eskers
#ORPH
Recruiting for Covid19 human challenge trials.
Anyone now what open orphans market cap was 12months ago. Just picked up on something CF stated on vox markets interview.
Interesting to find out that BMW have just joined Gfinity.
Our last Rns states that we are doing the advertising for Gfinity.
This could get exciting soon.
Finally somebody else has seen the interview.
Well done andinio.
Did you hear the part where he spoke about the rough cost of a test then x 3000 tests a day then that gives you an ideal of how much this company will be making on a 24hr basis.
Brilliant.
Like i posted earlier.
Listen to cathal in the interview he did with shares magazine on the 22nd and all your answer are in there including how much money we should be making every day once our machine is up and running.
1st of june things should get very interesting.
https://youtu.be/BBjvwtopf0I
Cathal friel on YouTube talking to shares magazine.
At one point he says he thinks the share price will go wild. Soon.It's 33 minutes long but well worth a listen and dated 22 may.
https://youtu.be/BBjvwtopf0I
· On track to deliver its first human pharmacokinetic data in H1 2019
· MHRA clearance expected in February 2019 and patients scheduled for dosing in March 2019
· Demonstration of bioequivalence to the reference product will trigger a £2 million milestone payment
· Rest of the World discussions for NXP001 commenced
Total milestone payments from NSB will therefore increase from £2.5 million to £3 million, following the addition of this second pre-clinical milestone, which Nuformix expects to achieve in Q1 2019. The resulting data will support regulatory submissions in China to facilitate market approval of multiple NXP001-derived products.
Hopefully this news to come soon will give the share price a boost.
Commenting, CEO, Toby Hayward said “I am delighted that we have agreed to proceed with the parties to acquire the La Luna project. This is a significant asset which, if the transaction proceeds, will be transformational for the shareholders of Red Leopard.” Its a big IF but lets hope they've done it.